eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2005
vol. 43
 
Share:
Share:
abstract:

ORGINAL ARTICLE
Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer’s disease

Tomasz Sobow
,
Iwona Kloszewska

Folia Neuropathol 2005; 43 (4): 340-344
Online publish date: 2006/01/06
View full text Get citation
 
Deregulation of APP metabolism is considered to be a key pathogenic event in Alzheimer’s disease. Data from cell cultures indicate that the secretion of Ab1-42 might be inhibited by cholinesterase inhibitors, possibly via M1 receptors stimulation. Treatment with tacrine, a dual acetyl- and butyrylcholinesterase inhibitor, had no significant effect on mean plasma Ab species concentrations. However, a correlation was observed between higher drug concentrations and lower Ab levels that might indicate an effect on APP metabolism with an increased a-cleavage.
Ab1-40 and Ab1-42 levels were measured in the plasma of 28 AD subjects by means of a commercially available ELISA before rivastigmine treatment and at week 2 after the first dose of the drug (3 mg/day) had been administered. Treatment with rivastigmine exhibited a significant effect on mean plasma concentrations of Ab1-42 (mean difference 7.8±8.4, t=-4.9, pmean difference 7.8±8.4, t=-4.9, p<0.001) with a negative correlation with the patients age (Pearson\'s R=-0.40, p=0.035). No significant effect on plasma Ab1-40 was observed.
The observed increase of mean levels of plasma Ab1-42 after rivastigmine treatment might indicate an effect of the drug on Ab metabolism, mobilization of Ab1-42 from deposits in the affected brain areas and a consecutive Ab1-42 brain-to-plasma efflux. The negative correlation between Ab1-42 plasma levels changes and age may be a sign of impairment of this process in the older patients. A large individual variation of the observed response, however, excludes drawing definite conclusions. Whether those subjects who respond to rivastigmine in terms of Ab1-42 plasma levels changes also respond clinically needs to be established.
keywords:

Alzheimer\'s disease, b-amyloid, plasma, Rivastigmine, cholinesterase inhibitors, butyrylcholinesterase

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.